Columbus Circle Investors cut its position in TherapeuticsMD, Inc. (NASDAQ:TXMD) by 5.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,017,780 shares of the company’s stock after selling 116,436 shares during the quarter. Columbus Circle Investors owned 0.93% of TherapeuticsMD worth $10,674,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. Managed Account Services Inc. raised its position in shares of TherapeuticsMD by 5.5% in the 2nd quarter. Managed Account Services Inc. now owns 19,103 shares of the company’s stock valued at $101,000 after buying an additional 1,000 shares in the last quarter. Amalgamated Bank raised its position in shares of TherapeuticsMD by 7.2% in the 2nd quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock valued at $104,000 after buying an additional 1,322 shares in the last quarter. Principal Financial Group Inc. raised its position in shares of TherapeuticsMD by 3.9% in the 2nd quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after buying an additional 818 shares in the last quarter. Traynor Capital Management Inc. raised its position in shares of TherapeuticsMD by 14.0% in the 2nd quarter. Traynor Capital Management Inc. now owns 22,799 shares of the company’s stock valued at $123,000 after buying an additional 2,799 shares in the last quarter. Finally, Virtu KCG Holdings LLC acquired a new position in shares of TherapeuticsMD in the 2nd quarter valued at approximately $157,000. Institutional investors own 76.82% of the company’s stock.
Several equities analysts have recently commented on TXMD shares. BidaskClub upgraded shares of TherapeuticsMD from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 25th. Cantor Fitzgerald restated an “overweight” rating and issued a $33.00 target price on shares of TherapeuticsMD in a research report on Tuesday, August 15th. Morgan Stanley started coverage on shares of TherapeuticsMD in a research report on Friday, September 8th. They issued an “equal weight” rating and a $6.00 target price for the company. Jefferies Group LLC restated a “buy” rating and issued a $15.00 target price on shares of TherapeuticsMD in a research report on Friday, August 11th. Finally, Oppenheimer Holdings, Inc. set a $10.00 target price on shares of TherapeuticsMD and gave the company a “buy” rating in a research report on Monday, October 16th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $14.72.
In related news, Director Tommy G. Thompson purchased 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 30th. The shares were bought at an average cost of $5.99 per share, with a total value of $29,950.00. Following the acquisition, the director now owns 3,555 shares of the company’s stock, valued at approximately $21,294.45. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 23.92% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece of content was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another publication, it was stolen and republished in violation of U.S. and international trademark and copyright laws. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/11/20/columbus-circle-investors-has-10-67-million-stake-in-therapeuticsmd-inc-txmd-2.html.
Shares of TherapeuticsMD, Inc. (NASDAQ TXMD) traded up $0.01 during trading on Monday, hitting $5.86. 233,205 shares of the company traded hands, compared to its average volume of 2,913,295. TherapeuticsMD, Inc. has a 12 month low of $3.50 and a 12 month high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last announced its quarterly earnings results on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.03. The company had revenue of $4.42 million for the quarter, compared to analyst estimates of $5.36 million. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The firm’s revenue was down 19.7% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.13) EPS. research analysts anticipate that TherapeuticsMD, Inc. will post -0.37 earnings per share for the current fiscal year.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD Inc. and related companies with MarketBeat.com's FREE daily email newsletter.